Neuroendocrine and cardiovascular effects of MDE in healthy volunteers.
E Gouzoulis, U Von Bardeleben, A Rupp, K A Kovar, L Hermle
Neuropsychopharmacology May 1993 DOI: 10.1038/npp.1993.20 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind placebo-controlled crossover study Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Healthy male volunteers |
| Intervention | 3 |
| Dose | 140 mg |
| Duration | Measurements every 20 minutes from 1:30 P.M. until 5:00 P.M. |
| Key points | MDE (140 mg orally) caused statistically significant and long-lasting increases in serum cortisol, prolactin, systolic blood pressure, and heart rate, with a trend toward blunted growth hormone secretion. The authors state these neuroendocrine and cardiovascular effects are comparable to those of other phenethylamines, except for the growth hormone effect. |
Abstract
The drug 3,4-methylenedioxyethamphetamine ([MDE] also known as "Eve") is a less toxic analog of 3,4-methylenedioxymethamphetamine (also known as "Ecstasy") with similar psychotropic effects in humans. In a double-blind placebo-controlled, cross-over study we administered 140 mg of MDE or placebo orally to eight healthy male volunteers at 1:30 P.M. Serum cortisol, prolactin (PRL), and growth hormone (GH) levels, as well as blood pressure, and heart rate were measured every 20 minutes until 5:00 P.M. Administration of MDE was followed by statistically significant long-lasting increases of serum cortisol, PRL, systolic blood pressure, and heart rate, and by a trend toward blunting of GH secretion. The neuroendocrine and cardiovascular effects of MDE are comparable to those of other phenethylamines with the exception of the effect on GH secretion.
Citations in the library
Cited by 13
- Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. Journal of Pharmacology and Experimental Therapeutics July 1, 1999
- Gender differences in the subjective effects of MDMA Psychopharmacology March 5, 2001
- Pharmacology of MDMA in Humans Annals of the New York Academy of Sciences September 1, 2000
- The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers Journal of Psychopharmacology May 1, 2000
- Acute Psychological and Neurophysiological Effects of MDMA in Humans Journal of Psychoactive Drugs June 1, 2002
and 8 more in the library
Cites 21
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
- Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals Science September 6, 1985
- The Psychological and Physiological Effects of MDMA on Normal Volunteers Journal of Psychoactive Drugs October 1, 1986
- Can Drugs Be Used to Enhance the Psychotherapeutic Process? American Journal of Psychotherapy July 1, 1986
and 16 more in the library